GRFS — GRIFOLS SA ADR (Healthcare >> Drug Manufacturers - General)
GRFS FAQ
What is GRFS's P/E ratio?
GRIFOLS SA ADR (GRFS) currently trades at a P/E ratio of 12.48.
What is GRFS's ROE?
GRIFOLS SA ADR reports a Return on Equity (ROE) of 7.61%.
What is GRFS's dividend yield?
GRIFOLS SA ADR offers a dividend yield of 2.32%.
What is GRFS's Deepscope Quality Score?
Deepscope rates GRFS's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GRFS?
Deepscope's AI Timing Score for GRFS is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GRFS belong to?
GRIFOLS SA ADR is classified under the Healthcare >> Drug Manufacturers - General sector on the NASDAQ exchange.
|
USD 7.64
Price
0.06
(0.79%)
Day Change
|
|
|---|
GRFS, ファンダメンタルスコアはok ( ファンダメンタル = 62) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROEが低い
平均ROEが低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
57% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 84 |
| Magic Formula Rank by ROA |
1759
|
| Magic Formula Rank by ROE |
1759
|
| Magic Formula Rank by ROIC |
1333
|
| Price | 7.64 |
| PBV / Sector |
0.66 / 2.84
GREAT
|
| Earning Per Share | 0.61 |
| PE / Sector |
12.48 / 24.53
GOOD
|
| PEG or PE/Growth / Sector |
0.11 / 0.08
GREAT
|
| Average 1M Daily Value |
4.77 M
GREAT
|
| Average 1W Daily Value |
4.27 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
43% |
| ポイントになる統計 |
|
62% |
| 配当 |
|
41% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:08:45 |
| Symbol | GRFS |
| Name | GRIFOLS SA ADR |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NASDAQ |
| Listed Shares | 680.58 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5,185.98 / 241,254.65 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Parque Empresarial Can Sant Joan, Barcelona, Spain, 08174
Phone: 34 935 71 22 00
Website: https://www.grifols.com
Employees: 25,000
Description: Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
Google